Dolloff N[Author] - Search Results

Year	Number of Results
2004	1
2005	1
2007	1
2008	2
2009	2
2010	2
2011	8
2012	3
2013	5
2014	1
2015	1
2017	1
2018	2
2019	5
2020	4
2021	0

1

ATF3 Coordinates Antitumor Synergy between Epigenetic Drugs and Protein Disulfide Isomerase Inhibitors.

Duncan RM, Reyes L, Moats K, Robinson RM, Murphy SA, Kaur B, Stessman HAF, Dolloff NG. Duncan RM, et al. Among authors: dolloff ng. Cancer Res. 2020 Aug 15;80(16):3279-3291. doi: 10.1158/0008-5472.CAN-19-4046. Epub 2020 Jun 19. Cancer Res. 2020. PMID: 32561529 Free PMC article.

2

Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects.

Allen JE, Krigsfeld G, Mayes PA, Patel L, Dicker DT, Patel AS, Dolloff NG, Messaris E, Scata KA, Wang W, Zhou JY, Wu GS, El-Deiry WS. Allen JE, et al. Among authors: dolloff ng. Sci Transl Med. 2013 Feb 6;5(171):171ra17. doi: 10.1126/scitranslmed.3004828. Sci Transl Med. 2013. PMID: 23390247 Free PMC article.

3

Targeted therapy of multiple myeloma.

Dolloff NG, Talamo G. Dolloff NG, et al. Adv Exp Med Biol. 2013;779:197-221. doi: 10.1007/978-1-4614-6176-0_9. Adv Exp Med Biol. 2013. PMID: 23288641 Review.

4

Design of Hydrazide-Bearing HDACIs Based on Panobinostat and Their p53 and FLT3-ITD Dependency in Antileukemia Activity.

Li X, Jiang Y, Peterson YK, Xu T, Himes RA, Luo X, Yin G, Inks ES, Dolloff N, Halene S, Chan SSL, Chou CJ. Li X, et al. Among authors: dolloff n. J Med Chem. 2020 May 28;63(10):5501-5525. doi: 10.1021/acs.jmedchem.0c00442. Epub 2020 May 6. J Med Chem. 2020. PMID: 32321249 Free PMC article.

5

Tuning isoform selectivity and bortezomib sensitivity with a new class of alkenyl indene PDI inhibitor.

Robinson RM, Reyes L, Duncan RM, Bian H, Strobel ED, Hyman SL, Reitz AB, Dolloff NG. Robinson RM, et al. Among authors: dolloff ng. Eur J Med Chem. 2020 Jan 15;186:111906. doi: 10.1016/j.ejmech.2019.111906. Epub 2019 Nov 21. Eur J Med Chem. 2020. PMID: 31787362 Free PMC article.

6

Emerging Therapeutic Strategies for Overcoming Proteasome Inhibitor Resistance.

Dolloff NG. Dolloff NG. Adv Cancer Res. 2015;127:191-226. doi: 10.1016/bs.acr.2015.03.002. Epub 2015 Apr 11. Adv Cancer Res. 2015. PMID: 26093901 Review.

7

Endoplasmic Reticulum Protein Disulfide Isomerase Shapes T Cell Efficacy for Adoptive Cellular Therapy of Tumors.

Hurst KE, Lawrence KA, Reyes Angeles L, Ye Z, Zhang J, Townsend DM, Dolloff N, Thaxton JE. Hurst KE, et al. Among authors: dolloff n. Cells. 2019 Nov 26;8(12):1514. doi: 10.3390/cells8121514. Cells. 2019. PMID: 31779147 Free PMC article.

8

Syrbactin proteasome inhibitor TIR-199 overcomes bortezomib chemoresistance and inhibits multiple myeloma tumor growth in vivo.

Pierce MR, Robinson RM, Ibarra-Rivera TR, Pirrung MC, Dolloff NG, Bachmann AS. Pierce MR, et al. Among authors: dolloff ng. Leuk Res. 2020 Jan;88:106271. doi: 10.1016/j.leukres.2019.106271. Epub 2019 Nov 12. Leuk Res. 2020. PMID: 31778912 Free PMC article.

9

Discovery platform for inhibitors of IgH gene enhancer activity.

Dolloff NG. Dolloff NG. Cancer Biol Ther. 2019;20(4):571-581. doi: 10.1080/15384047.2018.1538615. Epub 2018 Nov 27. Cancer Biol Ther. 2019. PMID: 30481117 Free PMC article.

10

Inhibitors of the protein disulfide isomerase family for the treatment of multiple myeloma.

Robinson RM, Reyes L, Duncan RM, Bian H, Reitz AB, Manevich Y, McClure JJ, Champion MM, Chou CJ, Sharik ME, Chesi M, Bergsagel PL, Dolloff NG. Robinson RM, et al. Among authors: dolloff ng. Leukemia. 2019 Apr;33(4):1011-1022. doi: 10.1038/s41375-018-0263-1. Epub 2018 Oct 12. Leukemia. 2019. PMID: 30315229 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results